Primacy of angiotensin converting enzyme in angiotensin-(1-12) metabolism

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 305, Issue 5, 2013, Pages

  Moniwa, Norihito ^a   Varagic, Jasmina ^a   Simington, Stephen W ^a   Ahmad, Sarfaraz ^a   Nagata, Sayaka ^a   VonCannon, Jessica L ^a   Ferrario, Carlos M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin converting enzyme; Angiotensin I; Angiotensin II; Angiotensin (1 12); Angiotensin (1 7); Blood pressure; Chymase; Hypertension

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN [1-12]; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN[1-7]; CHYMOSTATIN; DIPEPTIDYL CARBOXYPEPTIDASE; LISINOPRIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; TREATMENT OUTCOME; WISTAR KYOTO RAT;

ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-(1-12); ANGIOTENSIN-(1-7); BLOOD PRESSURE; CHYMASE; HYPERTENSION;

ANGIOTENSIN I; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; ANIMALS; BLOOD PRESSURE; CHYMASES; DISEASE MODELS, ANIMAL; HYPERTENSION; INFUSIONS, INTRAVENOUS; LISINOPRIL; MALE; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

EID: 84883435375     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00210.2013     Document Type: Article

References (38)

1. Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM. Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue. PLoS One 6: e28501, 2011.
2. Ahmad S, Varagic J, Westwood BM, Chappell MC, Ferrario CM. Uptake and metabolism of the novel peptide angiotensin-(1-12) by neonatal cardiac myocytes. PLoS One 6: e15759, 2011.
3. Ahmad S, Wei CC, Tallaj J, Dell=Italia LJ, Moniwa N, Varagic J, Ferrario CM. Chymase mediates angiotensin-(1-12) metabolism in normal human hearts. J Am Soc Hypertens 7: 128-136, 2013.
4. Arabidze GG, Belova LA, Chikhladze NM, Shapkina LS, Ogorodnikova OG, Kukharchuk VV. [Activity of chymotrypsin-like proteinases in patients with ischemic heart disease, arterial hypertension and nonspecific aortic arteritis]. Ter Arkh 72: 36-39, 2000.
5. Arnold AC, Isa K, Shaltout HA, Nautiyal M, Ferrario CM, Chappell MC, Diz DI. Angiotensin-(1-12) requires angiotensin converting enzyme and AT1 receptors for cardiovascular actions within the solitary tract nucleus. Am J Physiol Heart Circ Physiol 299: H763-H771, 2010.
6. Balcells E, Meng QC, Hageman GR, Palmer RW, Durand JN, Dell=Italia LJ. Angiotensin II formation in dog heart is mediated by different pathways in vivo and in vitro. Am J Physiol Heart Circ Physiol 271: H417-H421, 1996.
7. Balcells E, Meng QC, Johnson WH Jr, Oparil S, Dell=Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol Heart Circ Physiol 273: H1769-H1774, 1997.
8. Chappell MC. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension 50: 596-599, 2007.
9. Chatterjee PK, Brown PA, Cuzzocrea S, Zacharowski K, Stewart KN, Mota-Filipe H, McDonald MC, Thiemermann C. Calpain inhibitor-1 reduces renal ischemia/reperfusion injury in the rat. Kidney Int 59: 2073-2083, 2001.
10. Chitravanshi VC, Sapru HN. Cardiovascular responses elicited by a new endogenous angiotensin in the nucleus tractus solitarius of the rat. Am J Physiol Heart Circ Physiol 300: H230-H240, 2011.
11. Dell=Italia LJ, Husain A. Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr Opin Cardiol 17: 374-379, 2002.
12. Dell=Italia LJ, Meng QC, Balcells E, Straeter-Knowlen IM, Hankes GH, Dillon R, Cartee RE, Orr R, Bishop SP, Oparil S. Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation. Am J Physiol Heart Circ Physiol 269: H2065-H2073, 1995.
13. Ferrario CM. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control. Life Sci 86: 289-299, 2010.
14. Ferrario CM. New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension 55: 445-452, 2010.
15. Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Ann TE, Smith RD, Chappell MC. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 68: 2189-2196, 2005.
16. Ferrario CM, Varagic J, Habibi J, Nagata S, Kato J, Chappell MC, Trask AJ, Kitamura K, Whaley-Connell A, Sowers JR. Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol 296: H1184-H1192, 2009.
17. Husain A. The chymase-angiotensin system in humans. J Hypertens 11: 1155-1159, 1993.
18. Isa K, Garcia-Espinosa MA, Arnold AC, Pirro NT, Tommasi EN, Ganten D, Chappell MC, Ferrario CM, Diz DI. Chronic immunoneutralization of brain angiotensin-(1-12) lowers blood pressure in transgenic (mRen2)27 hypertensive rats. Am J Physiol Regul Integr Comp Physiol 297: R111-R115, 2009.
19. Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, Ferrario CM. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol 291: H2166-H2172, 2006.
20. Li M, Liu K, Michalicek J, Angus JA, Hunt JE, Dell=Italia LJ, Feneley MP, Graham RM, Husain A. Involvement of chymase-mediated angiotensin II generation in blood pressure regulation. J Clin Invest 114: 112-120, 2004.
21. Miyazaki M, Takai S, Jin D, Muramatsu M. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther 112: 668-676, 2006.
22. Moniwa N, Varagic J, Ahmad S, Voncannon JL, Ferrario CM. Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2. Lewis hypertensive rats. Ther Adv Cardiovasc Dis 6: 15-29, 2012.
23. Moniwa N, Varagic J, Ahmad S, Voncannon JL, Simington SW, Wang H, Groban L, Brosnihan KB, Nagata S, Kato J, Kitamura K, Gomez RA, Lopez ML, Ferrario CM. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension. Hypertension 61: 417-424, 2013.
24. Nagata S, Kato J, Kuwasako K, Asami M, Kitamura K. Plasma and tissue concentrations of proangiotensin-12 in rats treated with inhibitors of the renin-angiotensin system. Hypertens Res 35: 234-238, 2012.
25. Nagata S, Kato J, Kuwasako K, Kitamura K. Plasma and tissue levels of proangiotensin-12 and components of the renin-angiotensin system (RAS) following low-or high-salt feeding in rats. Peptides 31: 889-892, 2010.
26. Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun 350: 1026-1031, 2006.
27. Pat B, Chen Y, Killingsworth C, Gladden JD, Shi K, Zheng J, Powell PC, Walcott G, Ahmed MI, Gupta H, Desai R, Wei CC, Hase N, Kobayashi T, Sabri A, Granzier H, Denney T, Tillson M, Dillon AR, Husain A, Dell=Italia LJ. Chymase inhibition prevents fibronectin and myofibrillar loss and improves cardiomyocyte function and LV torsion angle in dogs with isolated mitral regurgitation. Circulation 122: 1488-1495, 2010.
28. Prosser HC, Forster ME, Richards AM, Pemberton CJ. Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. Cardiovasc Res 82: 40-50, 2009.
29. Prosser HC, Richards AM, Forster ME, Pemberton CJ. Regional vascular response to ProAngiotensin-12 (PA12) through the rat arterial system. Peptides 31: 1540-1545, 2010.
30. Takai S, Jin D, Miyazaki M. Multiple mechanisms for the action of chymase inhibitors. J Pharmacol Sci 118: 311-316, 2012.
31. Trask AJ, Jessup JA, Chappell MC, Ferrario CM. Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol Heart Circ Physiol 294: H2242-H2247, 2008.
32. Varagic J, Trask AJ, Jessup JA, Chappell MC, Ferrario CM. New angiotensins. J Mol Med 86: 663-671, 2008.
33. Volpe M, Savoia C, De PP, Ostrowska B, Tarasi D, Rubattu S. The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol 13, Suppl 3: S173-S178, 2002.
34. Wang Y, Gu Y, Lewis DF, Alexander JS, Granger DN. Elevated plasma chymotrypsin-like protease (chymase) activity in women with preeclampsia. Hypertens Pregnancy 29: 253-261, 2010.
35. Wei CC, Chen Y, Powell LC, Zheng J, Shi K, Bradley WE, Powell PC, Ahmad S, Ferrario CM, Dell=Italia LJ. Cardiac kallikrein-kinin system is upregulated in chronic volume overload and mediates an inflammatory induced collagen loss. PLoS One 7: e40110, 2012.
36. Wei CC, Hase N, Inoue Y, Bradley EW, Yahiro E, Li M, Naqvi N, Powell PC, Shi K, Takahashi Y, Saku K, Urata H, Dell=Italia LJ, Husain A. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest 120: 1229-1239, 2010.
37. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 12: 205S-213S, 1999.
38. Westwood BM, Chappell MC. Divergent pathways for the angiotensin-(1-12) metabolism in the rat circulation and kidney. Peptides 35: 190-195, 2012.